Aurora kinase a inhibitor MLN8237 suppresses pancreatic cancer growth.

Animals Apoptosis / drug effects Aurora Kinase A / antagonists & inhibitors Azepines / pharmacology Carcinoma, Pancreatic Ductal / drug therapy Cell Line, Tumor Cell Proliferation / drug effects Humans Mice Pancreatic Neoplasms / drug therapy Protein Kinase Inhibitors / pharmacology Pyrimidines / pharmacology Pancreatic Neoplasms
Apoptosis Aurora kinase Pancreatic cancer Senescence Xenograft

Journal

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
ISSN: 1424-3911
Titre abrégé: Pancreatology
Pays: Switzerland
ID NLM: 100966936

Informations de publication

Date de publication:
Jun 2022
Historique:
received: 21 03 2022
accepted: 25 03 2022
pubmed: 14 5 2022
medline: 15 6 2022
entrez: 13 5 2022
Statut: ppublish

Résumé

Pancreatic ductal adenocarcinoma (PDAC) is notorious for high mortality due to limited options of appropriate chemotherapy drugs. Here we report that Aurora kinase-A expression is elevated in both human and mouse PDAC samples. MLN8237, an inhibitor of Aurora kinase-A, efficiently reduced the proliferation and motility of PDAC cells in vitro as well as tumor growth in orthotropic xenograft model and genetic pancreatic cancer animal models (p53/LSL/Pdx-Cre mice) in vivo. MLN8237 exhibited tumor inhibitory effect through inhibiting proliferation and migration, and inducing apoptosis and senescence. These results provide the molecular basis for a novel chemotherapy strategy for PDAC patients.

Identifiants

DOI: 10.1016/j.pan.2022.03.019 PMID: 35550115 PMC: PMC9189053
pubmed: 35550115
pii: S1424-3903(22)00108-9
doi: 10.1016/j.pan.2022.03.019
pmc: PMC9189053
mid: NIHMS1806864
pii:
doi:

Substances chimiques

Azepines 0
MLN 8237 0
Protein Kinase Inhibitors 0
Pyrimidines 0
Aurora Kinase A EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

619-625

Subventions

Organisme : NCI NIH HHS
ID : K12 CA090628
Pays : United States
Organisme : NCI NIH HHS
ID : P20 CA102701
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA102701
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA255068
Pays : United States

Informations de copyright

Copyright © 2022 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest All authors have nothing to disclose.

Références

Oncol Lett. 2017 Dec;14(6):6571-6577
pubmed: 29163689
Biochem Pharmacol. 2012 Feb 15;83(4):452-61
pubmed: 22100984
Cancer Cell. 2003 Jan;3(1):51-62
pubmed: 12559175
Clin Cancer Res. 2007 May 15;13(10):3100-4
pubmed: 17505013
Cancer Cell. 2012 Feb 14;21(2):196-211
pubmed: 22340593
Cancer Res. 2002 Jul 15;62(14):4115-22
pubmed: 12124350
Mod Pathol. 2011 Jun;24(6):836-45
pubmed: 21441901
Nature. 2016 Mar 3;531(7592):47-52
pubmed: 26909576
Nat Med. 2004 Mar;10(3):262-7
pubmed: 14981513
J Clin Oncol. 2015 Jul 20;33(21):2399-404
pubmed: 26077240
Semin Oncol. 2015 Dec;42(6):832-48
pubmed: 26615129
Gastroenterology. 2017 Nov;153(5):1429-1443.e5
pubmed: 28764929
Cancer Res. 2005 Jan 1;65(1):130-6
pubmed: 15665288
Clin Cancer Res. 2003 Mar;9(3):991-7
pubmed: 12631597
Cell. 1995 Apr 7;81(1):95-105
pubmed: 7720077
Cancer. 2013 Feb 15;119(4):904-14
pubmed: 22972611
Clin Cancer Res. 2012 Apr 15;18(8):2210-9
pubmed: 22374334
Drug Des Devel Ther. 2015 Jan 17;9:575-601
pubmed: 25632225
J Cell Sci. 2017 Mar 15;130(6):1078-1093
pubmed: 28167680
Cell Death Dis. 2014 Nov 20;5:e1528
pubmed: 25412306
Nature. 2008 Sep 4;455(7209):119-23
pubmed: 18615013
Pancreas. 2008 Oct;37(3):e39-44
pubmed: 18815537
Sci Rep. 2016 Nov 08;6:35533
pubmed: 27824120
Mol Cancer Res. 2010 Mar;8(3):373-84
pubmed: 20197380
Oncogene. 2015 Jan 29;34(5):537-45
pubmed: 24632603
Br J Cancer. 2001 Mar 23;84(6):824-31
pubmed: 11259099
Cancer Res. 2010 Dec 1;70(23):9846-54
pubmed: 20935223
Ann Med. 2018 Jun;50(4):277-287
pubmed: 29537309
Cancer Res. 2005 Apr 1;65(7):2899-905
pubmed: 15805292
Oncol Rep. 2011 Jul;26(1):23-32
pubmed: 21479365
Mol Cancer Ther. 2014 Jan;13(1):122-33
pubmed: 24222664
Mol Cell Biol. 1997 Nov;17(11):6633-44
pubmed: 9343427
Transl Oncol. 2019 Apr;12(4):683-692
pubmed: 30844579
Ann Oncol. 2016 Oct;27(10):1855-60
pubmed: 27502708
Clin Adv Hematol Oncol. 2016 Feb;14(2 Suppl 1):12-3
pubmed: 27007010
Clin Cancer Res. 2004 Mar 15;10(6):2065-71
pubmed: 15041727
J Biol Chem. 2003 Dec 19;278(51):51786-95
pubmed: 14523000
Mol Cancer. 2015 May 20;14:106
pubmed: 25987188
Mol Cancer Res. 2013 Nov;11(11):1326-36
pubmed: 24008673
Cancer Res. 2019 Jul 1;79(13):3431-3444
pubmed: 30902796
Gynecol Oncol. 2011 Jan;120(1):11-7
pubmed: 20937525

Auteurs

Yuebo Zhang (Y)

Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.

Yong Ma (Y)

Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA; Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.

Ying Wang (Y)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.

Debabrata Mukhopadhyay (D)

Department of Biochemistry and Molecular Biology, Mayo Clinic, Jacksonville, FL, USA.

Yan Bi (Y)

Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.

Baoan Ji (B)

Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA. Electronic address: Ji.Baoan@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Aurora kinase a inhibitor MLN8237 suppresses...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › Aurora kinase a inhibitor MLN8237 suppresses...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-Serine-Threonine Kinases › Aurora kinases › Aurora kinase A › Aurora kinase a inhibitor MLN8237 suppresses...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azépines › Aurora kinase a inhibitor MLN8237 suppresses...
questionsmedicales.fr › Maladies endocriniennes › Tumeurs des glandes endocrines › Tumeurs du pancréas › Carcinome du canal pancréatique › Aurora kinase a inhibitor MLN8237 suppresses...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Aurora kinase a inhibitor MLN8237 suppresses...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › Aurora kinase a inhibitor MLN8237 suppresses...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Aurora kinase a inhibitor MLN8237 suppresses...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Aurora kinase a inhibitor MLN8237 suppresses...
questionsmedicales.fr › Maladies endocriniennes › Tumeurs des glandes endocrines › Tumeurs du pancréas › Aurora kinase a inhibitor MLN8237 suppresses...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Aurora kinase a inhibitor MLN8237 suppresses...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Aurora kinase a inhibitor MLN8237 suppresses...
questionsmedicales.fr › Maladies endocriniennes › Tumeurs des glandes endocrines › Tumeurs du pancréas › Aurora kinase a inhibitor MLN8237 suppresses...